A Widely Used Prescription Eye Drop Has Been Recalled Nationwide
Millions of prescription steroid eye drop bottles are being recalled across the United States after the U.S. Food and Drug Administration classified a voluntary recall by Lupin Pharmaceuticals as a Class II action due to the presence of a foreign substance in the product.
The FDA's enforcement report confirms that 2,530,182 bottles of prednisolone acetate ophthalmic suspension USP, 1% — manufactured by Lupin Limited in Pithampur, India, and distributed by Lupin Pharmaceuticals Inc. in the United States — are subject to the recall. The recall was initially posted June 4, 2026, with the FDA's Class II classification finalized on June 30, 2026.
Prednisolone acetate ophthalmic suspension is a corticosteroid eye drop commonly prescribed to reduce inflammation after eye surgery, treat uveitis, and manage allergic or inflammatory conditions affecting the conjunctiva, cornea, and the front of the eye. It is among the most widely used post-surgical ophthalmic medications in the country.
Why This Matters
Eye drops are applied directly to the eye — a sensitive, highly vascularized organ with direct proximity to the brain. Any contamination of an ophthalmic product creates a risk of ocular irritation, infection, or injury at the point of application. The presence of foreign material in a sterile eye medication is a manufacturing failure, not a normal product variation.
A Class II recall designation means the FDA has determined that use of the affected product may cause temporary or medically reversible adverse health consequences, with the probability of serious adverse health consequences considered remote. This is a middle-tier designation — more serious than a Class III recall but below the Class I classification reserved for products likely to cause serious injury or death.
The practical implication is straightforward: if you have one of the recalled bottles, do not continue using it. Contact your pharmacist or eye care provider for a replacement. With more than 2.5 million bottles distributed nationwide, there is a meaningful chance that patients currently using this medication — including those recovering from eye surgery — have an affected bottle.
What We Know So Far
The recall covers prednisolone acetate ophthalmic suspension USP, 1%, in three bottle sizes: 5 mL (NDC 70748-332-02), 10 mL (NDC 70748-332-03), and 15 mL (NDC 70748-332-04). All three sizes are part of the recall. The recall number is D-0655-2026.
The affected lot numbers cover dozens of batches with expiration dates ranging from July 2026 through March 2028, per the Optometry Times and Optometry Advisor reporting. This means bottles currently in pharmacies, medical practices, and patients' medicine cabinets — including bottles that appear to be several months from expiring — may be included.
The specific nature of the foreign material found in the product has not been publicly disclosed by Lupin or the FDA. This is common in enforcement reports, where manufacturers typically describe the defect category without providing specific characterization of the contaminant.
Lupin Limited received FDA approval for these eye drops in August 2024. The recall came approximately 22 months after that approval. The company manufactures a broad portfolio of generic pharmaceutical products, including multiple ophthalmic preparations.
Separately, Optometry Advisor noted that a different prednisolone acetate product — Pred Mild (10 mL), manufactured by AbbVie Inc. — was subject to a separate, earlier voluntary recall in late May 2026 due to failed stability specifications. That recall was classified as Class III and affected 2,736 bottles. These are two distinct products and two distinct recalls; patients should verify which manufacturer made their prescription.
Where the Risk Applies
The recalled bottles were distributed nationwide. There is no geographic concentration of risk — the product was available through retail pharmacies, hospital pharmacies, ophthalmology practices, and ambulatory surgery centers across all 50 states.
Patients most likely to have this medication include:
- People who recently underwent cataract surgery, LASIK, or other ocular surgical procedures (prednisolone acetate is routinely prescribed post-operatively)
- Patients being treated for uveitis, iritis, or other inflammatory conditions of the eye
- Patients managing allergic eye disease requiring corticosteroid therapy
- Patients being treated for keratitis or conjunctivitis with a steroid component
Post-surgical patients in particular should check their bottles immediately. If you received this medication after an eye procedure in the past several months, your bottle may fall within the recalled lot numbers.
What Doctors and Experts Say
The FDA's Class II classification carries a specific regulatory meaning. According to the FDA's enforcement framework, a Class II recall is defined as a situation where use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, while the likelihood of serious adverse health consequences is remote.
Ophthalmologists and optometrists are the primary points of contact for patients who need guidance on affected bottles. The FDA's enforcement report includes the full table of affected NDC codes and lot numbers, and eye care professionals are being advised to cross-reference any in-office or patient-held stock against that table.
The Ophthalmology Times specifically noted the FDA advisory that use of the affected eye drops be stopped immediately by patients who have recalled product.
What the Evidence Shows — and What It Does Not
The FDA has not published specific data on the number of adverse events reported in connection with the recalled product. The recall was initiated voluntarily by Lupin — meaning the company identified the issue and reported it, rather than the FDA discovering it through external surveillance.
The Class II classification reflects the FDA's assessment that the risk of serious harm is remote — not that harm is impossible. Foreign material in any sterile ophthalmic suspension represents a manufacturing defect that should not be present. The degree of risk depends on the nature of the foreign material, the concentration, and the individual patient's ocular health. Patients with corneal abrasions, post-surgical eyes with healing incisions, or existing inflammatory conditions may face heightened vulnerability to any extraneous material.
Patients who have been using the recalled product and experienced unexpected redness, irritation, pain, vision changes, or discharge should contact their eye care provider promptly and report the adverse event to the FDA's MedWatch system.
Who Faces the Greatest Risk
The patients most likely to be using this specific product — and therefore most likely to have a recalled bottle — include:
- Adults who recently underwent cataract surgery (prednisolone acetate is a standard post-operative eye drop used for weeks after the procedure)
- Patients with uveitis or iritis currently in a treatment cycle
- Adults being treated for allergic conjunctivitis or keratitis with corticosteroid drops
- Patients at ophthalmology or optometry practices that stock this specific generic formulation
Patients with a single eye or those who have had corneal transplants, glaucoma drainage device surgery, or other complex ocular procedures where even minor complications could have outsized consequences warrant particular attention.
Symptoms and Warning Signs to Watch For
Patients who have been using the recalled product should watch for any of the following, which may suggest an adverse reaction:
- Increased eye redness or irritation not attributable to the underlying condition
- Pain, burning, or stinging beyond what was previously experienced with the medication
- Increased discharge from the eye
- New blurry vision or visual changes
- Swelling of the eyelid or surrounding area
- Feeling of a foreign body or grittiness in the eye
These symptoms do not confirm that the contamination caused harm — they may also represent the underlying condition for which the drops were prescribed. However, any new or worsening ocular symptoms in a patient using a recalled product should be evaluated by an eye care provider.
Do not attempt to rinse the eye independently with water as a substitute for professional evaluation if symptoms are severe. If you experience sudden vision loss, severe pain, or significant swelling, seek emergency eye care immediately.
What You Can Do Now
- Check your bottle immediately. Find the NDC code on your bottle of prednisolone acetate ophthalmic suspension and compare it to the recalled codes: 70748-332-02 (5 mL), 70748-332-03 (10 mL), or 70748-332-04 (15 mL). If your bottle matches one of these NDC codes, check the lot number against the FDA's enforcement report .
- Stop using the product if it is affected. Do not continue using a recalled bottle, even if you have doses remaining in a post-surgical regimen.
- Contact your eye care provider or pharmacist. Your ophthalmologist, optometrist, or pharmacist can verify whether your specific lot is included and arrange a replacement prescription from an unaffected manufacturer or lot.
- Do not abruptly discontinue treatment without guidance. Post-surgical prednisolone acetate regimens are typically tapered — stopping suddenly without a replacement product can allow post-operative inflammation to return. Talk to your provider before discontinuing.
- Report adverse events. If you experienced any unexpected eye symptoms while using this product, report them to the FDA MedWatch program at 1-800-FDA-1088.
- Return affected bottles to your pharmacy. Do not discard recalled medication in regular trash or flush it down the toilet. Most pharmacies have take-back programs for recalled prescription medications.
Cost and Access: What Patients Should Know
Replacement prednisolone acetate eye drops from an unaffected manufacturer or lot are typically covered under the same prescription insurance coverage as the recalled product. Most insurance plans, including Medicare Part D and Medicaid, will cover a replacement fill when a recall is the documented reason.
Prednisolone acetate ophthalmic suspension is a generic medication available from multiple manufacturers. A 5 mL bottle typically retails for under $15 at major pharmacies without insurance. If cost is a barrier, GoodRx and similar discount programs can reduce out-of-pocket costs significantly.
Patients experiencing difficulty obtaining a replacement should call their prescribing physician or surgery center. Post-operative patients, particularly, should not delay getting a replacement — inflammation management after eye surgery is time-sensitive.
What Happens Next
The FDA may expand the recall to additional lots or sizes if further testing identifies contamination in previously unexamined batches. Lupin is expected to conduct an investigation into the manufacturing process that produced the affected lots, with results typically submitted to the FDA.
Patients and providers should check the FDA's enforcement report page for any updates. MedicalDaily will report on any expansion of the recall scope or FDA enforcement action against the manufacturer.
The Bottom Line
More than 2.5 million bottles of a widely used prescription steroid eye drop have been recalled due to foreign material contamination. If you use prednisolone acetate ophthalmic suspension made by Lupin — particularly if you are recovering from eye surgery or managing an inflammatory eye condition — check your bottle's NDC code and lot number against the FDA recall list today. Stop using affected product, contact your pharmacist or eye doctor for a replacement, and do not skip doses of your post-surgical regimen without medical guidance. The risk of serious harm is considered remote, but the risk of any harm at all from a contaminated sterile eye medication is entirely avoidable.
